Myelodysplastic Syndrome & Acute Myeloid Leukemia

MATTER:
Multidisciplinary Approach To Testing and Diagnosis, Evaluation of Risk, and Personalized Treatment Selection

Therapeutic Algorithm for Adult Patients with MDS and (Very) Low-Risk or Intermediate IPSS-R Risk Scores

(Very) Low Risk
Intermediate Risk
IPSS-R

Poor performance
Nonfit@

Nontransplant strategies

No poor risk features**
Nontransplant strategies
Failure

Good performance
Fit@

Available donor

Poor risk features**
Transplant strategies

** Poor risk features include:
- Poor-risk cytogenetics
- Persistent blast increase (> 50% or with > 15% BM blasts)
- Life-threatening cytopenias (neutrophil counts, < 0.3 \times 10^9/L; platelet counts, < 30 \times 10^9/L)
- High transfusion intensity \geq 2 units per months for 6 months
- Molecular testing should be seriously considered, in case of absence of poor-risk cytogenetic characteristics or persistent blast increase